Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis
nCRT is recommended for stage II esophageal cancer. In patients with stage III, those with "local invasive type" may greatly benefit from nCRT, while those with "regional metastatic type" may greatly benefit from nCT.
Authors
- Songbin Qin
- Long Chen (ORCID: https://orcid.org/0000-0002-9408-9696)
- Jiao Xue (ORCID: https://orcid.org/0000-0002-2395-7046)
- Xingyu Zhou (ORCID: https://orcid.org/0000-0002-7323-4997)
- Qi Zhao
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Precision Radiation Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/pro6.1249
- Citations
- 9
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.15